YH012 / Biocytogen, Radiance Biopharma - LARVOL DELTA

A first-in-class anti-HER2/TROP2 bispecific antibody-drug conjugate (YH012) exhibits potent anti-tumor efficacy (AACR 2023) - "Moreover, YH012 exhibited superior anti-tumor efficacy than benchmark antibodies in both HER2-positive and HER2-low xenograft models, indicating that YH012 has a potent and broad therapeutic effect. In summary, YH012 has the advantages of increased potency, tissue specificity, and reduced toxicity as a novel BsADC that can be further exploited to treat HER2 and TROP2 co-expressing tumors, especially HER2-low tumors."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • TACSTD2 • TROP2

Biocytogen to Participate in BioJapan2022 to Showcase Innovative R&D Platform, Bispecific ADC Program and Pipeline Progress [Google Translation] (Businesswire) - "Biocytogen Pharmaceuticals...will hold a seminar at the BioJapan 2022 conference on October 14 ( will be held on Friday). The seminar will be divided into three parts and will cover the following topics: Five fully human antibody drug discovery platforms based on RenMice TM: monoclonal antibody platform based on RenMab TM, bispecific antibody platform and bispecific ADC platform based on RenLite ^® , TCR mimic platform, GPCR platform; Progress of 'Project Integrum,' a large-scale project to develop antibody therapeutics against more than 1000 targets by evidence-based in vivo high-throughput screening; Key Assets of Bispecific ADCs Targeting HER2 x TROP2 and EGFR x c-MET (YH012 and YH013, respectively); Phase 1 Results of the Agonistic CD40 Monoclonal Antibody YH003, an Ongoing Multinational Phase 2 Clinical Trial in Patients with Unresectable/Metastatic PDAC."

Clinical • P1 data • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor